Targeted Cancer Therapy Market Research 2025: Advancements In Genomic Profiling and Precision Medicine, Increasing Prevalence of Various Type of Cancers - Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Targeted Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.

The Targeted Cancer Therapy Market was valued at USD 16.55 Billion in 2024, and is expected to reach USD 25.24 Billion by 2030, rising at a CAGR of 7.25%

This market forms a crucial segment of the broader oncology landscape, emphasizing precision treatment approaches that act on specific genetic mutations, proteins, or cellular environments contributing to cancer progression. Targeted therapies aim to maximize treatment efficacy while minimizing collateral damage often seen with traditional chemotherapy and radiation.

The industry includes an array of modalities such as monoclonal antibodies, kinase inhibitors, immune checkpoint inhibitors, and small molecules. Continued innovation, R&D investment, and active clinical trial pipelines are accelerating product development, thereby fostering improved patient outcomes and expanding therapeutic possibilities across various cancer types.

Key Market Drivers

Increasing Prevalence of Various Type of Cancers

Rising cancer prevalence globally is a major force fueling the demand for targeted cancer therapies. As of 2020, cancer accounted for nearly 10 million deaths annually, making it a dominant health and economic concern. Pediatric cancer remains a high-priority area, with roughly 400,000 new diagnoses each year. Patterns of incidence vary by geography, with cervical cancer topping the list in 23 countries, reflecting inequalities in HPV vaccination and screening.

This variation signals untapped markets for tailored diagnostics and therapies. Lung cancer, representing about 12.4% of all new cancer cases, remains the deadliest, contributing to 18.7% of all cancer-related fatalities. As aging populations, lifestyle shifts, and environmental exposures drive global cancer rates upward, targeted therapies provide more effective, less toxic alternatives to conventional treatments. Their ability to deliver personalized, gene-specific interventions positions them as essential tools in modern oncology, especially in light of these growing epidemiological trends.

Key Market Challenges

High Cost and Side Effects Associated with the Targeted Therapies

The considerable cost of targeted cancer treatments presents a substantial hurdle to widespread adoption. Advanced therapies such as monoclonal antibodies and gene modulators demand high manufacturing investment and specialized administration, resulting in elevated prices for patients and healthcare systems. According to the American Association for Cancer Research, the U.S. could see national cancer-related costs exceed USD 245 billion by 2030 - an increase of over 30% since 2015.

Patients undergoing initial, ongoing, or end-of-life cancer care can incur average annual costs ranging from USD 5,300 to over USD 41,800. This economic burden affects access to care and can lead to financial distress for both patients and healthcare providers. Additionally, while targeted therapies are generally safer than traditional chemotherapy, they are not devoid of side effects, including immune-related adverse events or organ toxicity. These challenges call for innovative cost-control strategies, reimbursement policy revisions, and research into affordable alternatives to sustain market growth.

Key Market Trends

Advancements In Genomic Profiling and Precision Medicine

The integration of genomic profiling and precision medicine is transforming cancer treatment, driving greater adoption of targeted therapies. Next-generation sequencing (NGS) and liquid biopsy technologies now enable precise identification of genetic mutations that drive cancer, allowing clinicians to tailor treatment plans based on each patient's unique tumor profile.

These innovations have led to more effective, personalized therapies with fewer adverse effects. Precision medicine is also becoming instrumental in tracking disease progression and resistance patterns, enabling real-time adjustments to treatment. As these tools become more accessible, healthcare systems worldwide are increasingly implementing genomic-based protocols. This evolution in oncology practice underscores the growing reliance on targeted treatments and supports their rising use as a mainstay in cancer care strategies.

Key Attributes:

Report Attribute	Details
No. of Pages	185
Forecast Period	2024 - 2030
Estimated Market Value (USD) in 2024	$16.55 Billion
Forecasted Market Value (USD) by 2030	$25.24 Billion
Compound Annual Growth Rate	7.2%
Regions Covered	Global

Report Scope:

Key Market Players

• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Service Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.

Targeted Cancer Therapy Market, By Therapy Type:

• Hormone Therapies
• Monoclonal Antibodies
• Signal Transduction Inhibitors
• Gene Expression Modulators
• Apoptosis Inhibitors
• Others

Targeted Cancer Therapy Market, By Disease Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Melanoma
• Lymphoma
• Others

Targeted Cancer Therapy Market, By End User:

• Hospitals & Clinics
• Cancer & Radiation Therapy Centers
• Academic & Research Institutions

Targeted Cancer Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

For more information about this report visit https://www.researchandmarkets.com/r/mxsrb9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.